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Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and advanced hepatic fibrosis is a major risk
factor for HCC. Hepatic fibrosis including liver cirrhosis and HCC are mainly induced by persistent hepatitis B or C
virus infection, with approximately 500 million people infected with hepatitis B or C virus worldwide. Furthermore,
the number of patients with non-alcoholic fatty liver disease (NAFLD) has recently increased and NAFLD can
progress to cirrhosis and HCC. These chronic liver diseases are major causes of morbidity and mortality, and the
identification of non-invasive biomarkers is important for early diagnosis. Recent advancements in quantitative and
large-scale proteomic methods could be used to optimize the clinical application of biomarkers. Early diagnosis of
HCC and assessment of the stage of hepatic fibrosis or NAFLD can also contribute to more effective therapeutic
interventions and an improve prognosis. Furthermore, advancements of proteomic techniques contribute not only
to the discovery of clinically useful biomarkers, but also in clarifying the molecular mechanisms of disease
pathogenesis by using body fluids, such as serum, and tissue samples and cultured cells. In this review, we report
recent advances in quantitative proteomics and several findings focused on liver diseases, including HCC, NAFLD,
hepatic fibrosis and hepatitis B or C virus infections.
Introduction
Diagnostic methods for hepatocellular carcinoma (HCC)
include imaging, such as abdominal ultrasonography
and computed tomography (CT), and measurement of
serum tumor markers. Alpha-fetoprotein (AFP), AFP
lectin fraction L3 (AFP-L3), and des-gamma-carboxy
prothrombin (DCP, also known as PIVKA-II) are widely
used clinically as serum tumor markers of HCC. How-
ever, the sensitivity of AFP or DCP for detecting early
stage HCC is only 30-60% [1-4]. Although combination
measurements of AFP and DCP can improve the diag-
nostic performance, the diagnostic accuracy is still low
for HCC lesions of ≤2 cm. Therefore, the development
of a new diagnostic method for early stage HCC is
needed to improve outcomes [5-7].
The main cause of liver cirrhosis and HCC is persistent
hepatitis B or C virus infection. The degree of hepatic
fibrosis is associated with the occurrence of HCC, and
serum hyaluronic acid and type IV collagen levels are
used for diagnosis of hepatic fibrosis including cirrhosis,
but these markers do not always reflect the stage of hepa-
tic fibrosis assessed by liver biopsy [8,9]. In addition, the
incidence of nonalcoholic fatty liver diseases (NAFLD)
has increased worldwide, but no specific biomarker is
available and invasive liver biopsy is still required for
definite diagnosis of NAFLD, especially for nonalcoholic
steatohepatitis (NASH), which can progress to cirrhosis
and HCC [10,11]. Therefore, there is a need to identify
blood (serum or plasma) markers that are specific for
early diagnosis of HCC, prediction of carcinogenesis
from liver cirrhosis, progression of liver cirrhosis, and
diagnosis of NASH. These analyses may also aid in the
elucidation of the mechanism(s) underlying the patho-
genesis of hepatitis and hepatocarcinogenesis.
Proteomics is the term used for exhaustive analysis of
protein structure and function in an organ or tissue. The
levels of gene expression and protein production are not
necessarily proportional, and protein activity is frequently
regulated by posttranslational modifications such as
phosphorylation [12,13]. Proteomics is useful for elucida-
tion of the pathology and discovery of disease markers
for HCC and chronic liver diseases. Serum and plasma
are readily used as clinical samples since they can be
obtained using less invasive methods. If a biomarker
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cacy of treatment is identified in serum or plasma, it can
be easily applied for early or differential diagnosis of dis-
eases. Recent advances in methods for mass spectro-
metric analysis, including protein labeling and amino
acid analysis, facilitate highly sensitive and exhaustive
proteomic analysis of patient samples. These advances in
proteomics techniques have promoted exploration of bio-
markers for malignant tumors including HCC and for
chronic liver diseases including liver cirrhosis, NAFLD
and chronic hepatitis B or C. In this review, we provide
an overview of recent findings in proteomic analysis of
those liver diseases.
A - Clinical proteomics
For the efficient discovery of biomarkers, more quantita-
tive and reproducible techniques are required. Therefore,
differential analysis of protein expression is frequently
used in clinical proteomics. Quantitative proteomic
approaches can be separated into both labeling (Table 1)
and labeling-free methods (Table 2), and the labeling
method is separated into gel-based and non-gel-based
methods. The most typical method of the gel-based
differential approach is two-dimensional fluorescence dif-
ference gel electrophoresis (2D-DIGE) [14,15]. On the
other hand, non-gel-based methods include some stable
isotope-labeling methods, such as cleavable isotope-
coded affinity tags (cICAT) [16], stable isotope labeling
by amino acids in cell culture (SILAC) [17,18], 2-nitro-
benzenesulfenyl (NBS) labeling [19] and protein quantita-
tion using isobaric tags for relative and absolute
quantitation (iTRAQ) [20]. In addition, labeling-free
methods; surface enhanced laser desorption ionidization
(SELDI) methods [21] and ClinProt
® systems [22] based
on affinity-column or -beads chromatographic methods
were beneficial to analyze the blood samples (Table 2).
Moreover, molecular information can be obtained from
comparison of multiple samples in a single analysis with
these methods. The techniques of separation and
detection on mass spectrometric analysis and molecular
identification have also progressed with improvement
in accuracy. The development of high-sensitivity,
high-throughput, and exhaustive analytical methods has
facilitated identification of trace proteins in biological
samples, and clinical proteomics is now performed
using new protein analysis techniques. However, these
are mostly basic studies, rather than disease-based
proteomics useful for bedside diagnosis and prediction of
therapeutic effects. Thus, proteomics studies of the asso-
ciation between clinical data and results obtained from
cells, tissues and clinical samples are required.
B - Proteomic analysis of hepatocellular
carcinoma
1 - Serum proteomics in patients with HCC
Protein separation by 2-dimensional electrophoresis
(2-DE) is a well-established and widely used method
with easy handling and good reproducibility. In a 2-DE
study of protein expression in sera of 5 patients with
HCC (2 hepatitis B virus surface [HBs] antigen-positive
cases, 2 hepatitis C virus [HCV] antibody-positive cases,
and one case negative for both] and healthy subjects,
317 proteins were separated and identified, of which 6
(annexin VI isoform 1, complement component 9, ceru-
loplasmin, and serum amyloid A4, A2 and A1 isoform 2)
were proposed as diagnostic markers for HCC [23]. In
Table 1 Quantitative proteomic techniques that have been applied to clinical proteomics using labeling method
Methods Type of
method
Labeling reagents Interests Comparable
number of
samples/assay
References
2D-DIGE Gel-
based
Cy2, Cy3, Cy5, IC3-OSu, IC5-OSu Most frequently used gel-based method 2 samples [14], [15]
cICAT Non-gel
based
12C-ICAT (light)
13C-ICAT (heavy)
Labeled to cysteine thiol group
Most frequently used isotope labeling
method
2 samples [16]
SILAC Non-gel
based
12C- or
14N-lysine and arginine (light)
13C- or
15N-lysine and arginine (heavy)
Incorporated into cultured cells
Pre-labeling method.
Cell lysates and conditioned media can
be analyzed.
2 samples [17], [18]
NBS Non-gel
based
12C-NBS (light)
13C-NBS (heavy)
Labeled to tryptophan indole group
Simple MS spectra can be obtained
because there is less tryptophan in
protein sequences.
2 samples [19]
iTRAQ Non-gel
based
Isobaric tags (m/z 305, in total)
(m/z, reporter) + (m/z, balancer):
(113) + (192), (114) + (191), (115) + (190), (116) +
(189), (117) + (188), (118) + (187), (119) + (186),
(121) + (183)
Labeled to lysine amino group
Expression ratio can be used to quantify
the signal intensity of reporter peaks.
Many samples can be assayed in one
experiment.
2 ~ 8 samples [20]
2D-DIGE; two-dimensional fluorescence difference gel electrophoresis, cICAT; cleavable isotope-coded affinity tags, SILAC; stable isotope labeling by amino acids
in cell culture, NBS; 2-nitrobenzenesulfenyl, iTRAQ; isobaric tags for relative and absolute quantitation, Cy; cyanine.
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investigated by 2-DE, 8 proteins with significant differ-
ences in expression levels compared to controls were
identified (transferrin, transthyretin, a1-antitrypsin, clus-
terin, haptoglobin a2 chain, ceruloplasmin, heat-shock
protein 27 [HSP27], and a-fetoprotein), and HSP27 was
positive in 90% of the HCC cases, showing its value for
HCC screening [24]. Useful diagnostic markers may be
discovered in proteins directly identified by 2-DE separa-
tion of patient serum, followed by extraction of protein
spots from the gel and identification by peptide-mass fin-
gerprinting (PMF) and MS/MS analysis. However, albu-
min, globulin, transferrin, and antitrypsin account for
about 90% of the serum protein composition, and the
large amounts of these proteins interfere with separation
of serum proteins by 2-DE, and make separation and
analysis difficult. To analyze serum using 2-DE, removal
of these abundant proteins and subsequent detection of
changes in trace protein levels are necessary. Ang et al.
removed albumin by pretreatment of sera from patients
with HCC and chronic liver disease (CLD) using lectin
and then compared the glycosylated haptoglobin expres-
sion level using 2-DE [25]. Expression of glycosylated
haptoglobin was increased in the HCC group, and the
level was higher in advanced HCC compared to early
stage HCC, suggesting that glycosylated haptoglobin is
useful for diagnosis and prediction of the HCC stage
[25]. These findings also suggest that pretreated serum is
better than non-treated serum for 2-DE analysis.
There are two methods of serological diagnosis using the
ProteinChip SELDI system: one uses identification of indi-
vidual proteins and functional analysis, and the other is
based on a classification (decision tree) method established
by data mining without protein identification.
Identification of a protein corresponding to a target peak
is difficult using the ProteinChip SELDI system, and the
classification-based diagnostic method (multi-marker ana-
lysis) is frequently used, in which identification of each
protein corresponding to an individual peak is not neces-
sary. The disease and control groups are differentiated
based only on the expression levels of several protein
peaks. We established a classification method based on 7
peaks that were highly distinguishable between HCV-
related HCC and HCV-related CLD, and showed that this
method is applicable for diagnosis of both early stage and
advanced HCC [26]. This approach was capable of detect-
ing HCC earlier than detection of tumorous lesions by
abdominal ultrasonography, and was more useful for early
diagnosis than current tumor markers such as AFP and
DCP. Similarly, Zinkin et al. developed a diagnostic
method using 11 protein peaks detected by the Pro-
teinChip SELDI system, and found a sensitivity and speci-
ficity for diagnosis of HCV-related HCC of 79% and 86%,
respectively [27]. The diagnostic sensitivity and specificity
do not differ significantly from those of methods using
current HCC markers (AFP, AFP-L3 fraction, and DCP),
but the performance for diagnosis of small HCC of ≤2c m
was better than that for methods using current markers.
He et al. selected 3 protein peaks (5890, 11615, and
11724 Da) in serum that showed significant differences
in HBV-related HCC patients compared to HBV
patients without HCC, and found that HBV-related
HCC could be diagnosed in almost 100% of cases based
on these proteins [28]. The SELDI method was com-
bined with 2-DE to identify the protein with a peak at
11615 Da as serum amyloid A (SAA). However, the
positive rate was also high in patients with HBV-related
CLD in this analysis, indicating that the method is not
Table 2 Quantitative proteomic techniques that have been applied to clinical proteomics using labeling-free method
Methods Types of chips or magnetic
beads
Interests References
ProteinChip
SELDI
IMAC30 (metal modified),
CM10 (cation exchanging),
WCX2 (weak cation
exchanging)
Q10 (anion exchanging),
H50 (reverse-phase),
H4 (reverse-phase),
NP20 (normal-phase),
Gold
Analyses: a few μl of serum/plasma (without removal of abundant proteins), urine, cell/
tissue lysates and conditioned media
Identification: MS/MS, LC-MS/MS
[21]
ClinProt
® Profiling: WCX, WAX, HIC8,
IMAC-Cu
Large-protein beads: HIC1,
HIC3
Peptides beads: HIC18
Phospho beads: IMAC-Fe
Glyco beads: LAC ConA,
ConAC boronic
Antibody capture beads: IAC
ProtG
Performance: Many samples can be assayed in parallel.
[22]
SELDI; surface enhanced laser desorption ionidization, MS; mass spectrometry, LC; liquid chromatography.
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HBV-related HCC or CLD could be distinguished from
healthy subjects by multi-marker serum analysis with
sensitivity and specificity of 90% or higher [29], but it is
doubtful whether this method could be used for differ-
entiation of HCC from CLD. Similarly, sensitivity of
100% and specificity of 92 or 97% have been reported
for diagnosis of HBV-related HCC [30], but the control
group consisted of healthy subjects without CLD and
the utility for early diagnosis of HCC in patients with
cirrhosis is doubtful. Göbel et al. established a method
for differentiation of HCV-related HCC from liver cir-
rhosis without HCC using 4 protein peaks at 7486,
12843, 44293, and 53598 Da (multi-marker analysis),
and found that the method was useful for diagnosis of
early stage HCC [31]. Ward et al. also reported a multi-
marker analysis with 94% sensitivity, 86% specificity, and
0.92 AUROC [32]. Thus, multi-marker analysis is useful
for diagnosis. However, a ProteinChip SELDI system is
necessary for analysis, and this system is expensive com-
pared with commercially available kits such as those for
ELISA, and not all facilities can use this system. More-
over, the peak protein intensity detected by a protein
chip system may vary among analytical devices and
facilities, and further technical advances are needed for
clinical application of multi-marker analysis for diagno-
sis of early stage HCC (Table 3).
In analysis using cICAT and liquid chromatography-
electrospray ionization tandem mass spectrometry (LC-
ESI-MS/MS), Kang et al. compared serum proteins
between 9 cases of HCC and 9 cases of liver cirrhosis, and
identified 31 proteins with differences in expression levels.
Of these proteins, significantly enhanced expression of a1-
acid glycoprotein (AGP) was observed in the HCC valida-
tion group (HCC; N = 52, liver cirrhosis; N = 40), showing
that AGP is a candidate serum diagnostic marker for HCC
[33]. Thus, serum proteomic analysis using a combination
of cICAT and LC-ESI-MS/MS can be used for direct iden-
tification of potential protein markers.
AFP and DCP are frequently used in current diagnosis
of HCC. These proteins are directly expressed by
tumors and their blood levels are reduced by local treat-
ment or tumor resection. Therefore, they serve as
indices for diagnosis, therapeutic effect and recurrence.
In contrast, the proteins identified by serum protein
expression analysis described above are not necessarily
produced by the tumor (for example, they may be pro-
duced by immune cells that act on tumor cells) and this
may be limitation of current biomarker exploration by
serum analysis. Moreover, some proteins in HCC
change with progression of the pathology of the under-
lying diseases of chronic hepatitis and liver cirrhosis.
Therefore, specificity is of importance in clinical proteo-
mic analysis using serum from patients with HCC.
2 - Tissue proteomics in patients with HCC
HCC tissue has been widely used in proteomics because
a large amount of tissue can be obtained relatively easily
from surgical specimens [34-41]. In a study in which
protein expression in liver tissue was investigated by
2-DE in 40 cases of HBV-related HCC and 36 control
subjects (20 patients with liver cirrhosis and 16 normal
liver tissues from residual grafts of liver donors), 14 pro-
teins with ≥2-fold changes in expression level were iden-
tified in patients with HCC compared to the controls
[34]. Of these proteins, vimentin expression was
Table 3 The peaks detected by ProteinChip SELDI in patients with hepatocellular carcinoma
Subjects Protein/Peptide Peaks (m/z) Type of
Protein Chip
Identification References
HCV-related HCC
vs. non-HCC
3444, 3890, 4067, 4435, 4470, 7770 CM10 ND [26]
HCC
vs. non-HCC (cirrhosis)
3687, 3906, 26457
11853, 11873, 11887, 13391
11319, 17783, 17906, 18021
CM10,
IMAC30,
H50,
13391-Da;
Cystatin C
[27]
HBV-related HCC
vs. non-HCC
5890, 11615, 11724 IMAC30-Cu ND [28]
CHB
LC
HCC
(vs. Healthy control)
22842 (up), 2957, 2049 (down), 2049 (up), 3166 (down),
23381, 28040 (up),
2018 (down)
WCX2 ND [29]
HBV-related HCC
vs. Healthy control
7777, 9250, 16200 WCX2 ND [30]
HCV-related HCC
vs. HCV-related LC
2873, 6646, 7775, 10525,
67867
CM10 6646-Da; Apolipoprotein C-I [31]
HCV-related HCC
vs. HCV-related LC
22960, 23530 IMAC30 ND [32]
SELDI; surface-enhanced laser desorption and ionization mass spectrometry, HCV; hepatitis C virus, HCC; hepatocellular carcinoma, HBV; hepatitis B virus, CHB;
chronic hepatitis B, LC; liver cirrhosis, ND; not done.
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level was also elevated in serum from the HCC patients,
which was useful for diagnosis of HCC lesions of ≤2 cm.
Comparison of HCC and normal liver tissues using
2D-DIGE has shown reduced expression levels of pro-
teins associated with metabolism and increased expres-
sion of stress-related proteins of the HSP family in
HCC, with aldo-keto reductase 1C2, thioredoxin, and
transketolase proposed as HCC markers [35,36]. Luk et
al. analyzed liver tissue of 146 patients by 2-DE+MS/MS
and detected 1800 protein spots. Three of these protein
spots with strong expression in HCC were identified as
Hsp27, Hsp70 and glucose-regulated protein (GRP) 78.
Hsp27 was found to be highly correlated with AFP, and
GRP78 was associated with venous tumor invasion [37].
Sun et al. performed protein expression analysis to
search for HCC biomarkers using liver tissue samples
from 59 patients with liver diseases (39 with HCC and
20 with liver cirrhosis) and 16 healthy subjects, and 63
plasma samples (35 patients with HCC, 16 with liver cir-
rhosis, and 12 healthy subjects). In both liver tissue and
plasma, lamin B1 (LMNB1) expression was significantly
enhanced in HCC patients compared to healthy subjects,
and the LMNB1 expression level was associated with the
cancer stage, leading to the conclusion that this protein
is a useful biomarker for early stage HCC [38]. An
increased clathrin heavy chain level and a lower formi-
minotransferase cyclodeaminase level in 2-DE analysis
of HCC tissue have also been proposed to be useful for
diagnosis of early stage HCC [39], and APC-binding
protein EB1 expression in resected HCC specimens has
been related to the survival and recurrence rates after
resection [40].
Use of whole resected liver specimens containing HCC
for proteomic analysis allows detection of proteins
expressed not only by cancer cells, but also by cells infil-
trating around the tumor and by interstitial cells. Selec-
tion of cancer tissue by laser capture microdissection
(LCM) followed by 2-dimensional liquid chromatogra-
phy tandem mass spectrometry (2D-LC/MS-MS) can be
used to identify proteins that differ quantitatively
between disease and control tissue [41]. This approach
is useful for analysis of surgical samples and may help
to improve the understanding of the mechanism of car-
cinogenesis in HCC.
C - Proteomic analysis of nonalcoholic fatty liver
disease (NAFLD), hepatic fibrosis and liver
cirrhosis
1 - Serum proteomics of NAFLD, hepatic fibrosis and liver
cirrhosis
The number of cases of NAFLD including NASH has
shown a recent increase, and NASH is a risk factor for
HCC. NASH has a pathology similar to that of alcoholic
liver diseases and is accompanied by inflammation and
fibrosis that progresses to liver cirrhosis and HCC.
Excess nutrition, obesity, insulin resistance, and oxida-
tive stress are thought to be involved in the develop-
ment and progression of NASH, but the molecular
mechanisms remain uncertain. About 30% of subjects in
a health check-up in Japan showed abnormalities in
serum markers of liver function such as ALT, AST and
g-GTP, and most cases were assumed to be NAFLD.
Identification of patients with NASH among those with
NAFLD is very important for prevention of liver cirrho-
sis and HCC through intensive treatment. However,
invasive liver biopsy is currently required for diagnosis
of NASH, since no specific serum marker is available
for use in a noninvasive test [10]. In serum proteomics
in patients with NAFLD, four apolipoproteins and CD5
antigen-like protein (CD5L) were identified by 2-DE
analysis. Of these proteins, CD5L reflects the severity of
hepatic fibrosis in NAFLD and its serum level increases
in cases with severe fibrosis, suggesting that it may serve
as a diagnostic marker of NASH [42]. An analysis of
sera of patients with NAFLD using the ProteinChip
SELDI system identified 4 protein peaks with significant
changes in patients with NASH compared to obese
patients without NAFLD [11]. These peaks may be use-
ful for diagnosis of NASH, but the corresponding pro-
teins have yet to be identified. Interestingly, mRNA
expression in liver tissue was analyzed using a microar-
ray in the same patients in this study, and this analysis
may advance the understanding of the molecular
mechanism of development and progression of NAFLD.
Currently, the association between serum protein
expression and gene expression in liver tissue is unclear.
Bell et al. analyzed sera of 85 patients with NAFLD,
including cases of NASH and simple fatty liver by LC/
MS-MS and identified 1738 proteins, of which 9
reflected differences in fibrosis among the NASH
patients and 21 were proposed as useful biomarkers to
distinguish NASH (F3/F4) with advanced fibrosis from
simple fatty liver [43]. Unfortunately, no single protein
for discrimination between simple fatty liver and NASH
was obtained in this analysis. A panel diagnostic method
using fibrinogen b chain, retinol binding protein 4,
serum amyloid P component, lumican, transgelin 2,
CD5L, complement component C7, insulin-like growth
factor acid labile subunit, and transgelin 2 has been
developed that discriminates among healthy subjects,
patients with simple fatty liver, and patients with NASH
with high power. In this report, serum was separated by
nano-HPLC in proteomic analysis, and proteins were
identified and quantified by electrospray ionization (ESI)
[43]. Such combination method has high-resolution and
relatively favorable quantitative performance with a very
small amount of sample, therefore is capable of
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its use. However, whether the identified proteins are
t r u l ys p e c i f i ct oN A F L Da n du s e f u lf o rd i a g n o s i so f
NASH remains to be investigated.
Proteomic analysis in patients with liver cirrhosis has
also been performed to search for hepatic fibrosis mar-
kers. Poon et al. developed a scoring system for diagno-
sis of hepatic fibrosis using 10 factors: 7 protein peaks
detected using the ProteinChip SELDI system, and the
ALT, total protein, and bilirubin levels in serum. Using
this approach, liver cirrhosis was diagnosed with 94%
sensitivity and 91% specificity [44]. Morra et al. also
showed that a differentiation method based on 8 protein
peaks was more useful for evaluation of hepatic fibrosis
than the existing Fibro Test (an method that uses a2-
macroglobulin, haptoglobin, apolipoprotein A1, total
bilirubin, and g-GTP) [45]. Göbel et al. used 5 serum
protein peaks in development of a multi-marker method
to differentiate between cirrhotic and non-cirrhotic
livers (F1 and F2), and showed that this method could
be used to diagnose liver cirrhosis with 80% sensitivity
and 67% specificity [31].
In 2-DE analysis of sera from patients with HCV-
related CLD, the levels of inter-alpha-trypsin inhibitor
heavy chain H4 (ITIH4) fragments, a1-antichymotrypsin,
apolipoprotein L1, prealbumin, albumin, paraoxonase/
arylesterase 1, and zinc-a2-glycoprotein were reduced
and those of CD5 antigen-like protein (CD5L) and b2
glycoprotein I (b2GPI) were elevated in the liver cirrhosis
group [9]. Using a similar method, the levels of Mac-2-
binding protein, a2-macroglobulin and hemopexin were
found to be elevated and those of a1-antitrypsin, leucine-
rich a2-glycoprotein and fetuin-A were decreased in
advanced liver fibrosis [46]. Identification of serum pro-
tein peaks that are altered in liver cirrhosis and verifica-
tion of their utility in the diagnosis of liver cirrhosis may
lead to the discovery of novel diagnostic markers. Calle-
waert et al. have also recently reported an interesting gly-
coproteomics approach in developing the methodology
for a DNA sequencer-based total serum protein-linked
N-glycans [47]. Their methodology allows for high-
throughput fingerprinting and sequencing of N-glycans
that are present on picomolar amounts of glycoproteins.
Using this method, they compared the serum protein-
linked N-glycan profiles from compensated cirrhotic and
non-cirrhotic chronic liver disease patients, to success-
fully distinguish the pathogenesis of both disease popula-
tions with 79% sensitivity and 86% specificity [48].
2 - Tissue proteomics of NAFLD, hepatic fibrosis and liver
cirrhosis
To predict the progression of NASH and/or hepatic
fibrosis, it is important to gain a better understanding of
the pathogenesis and molecular mechanism(s)
responsible. To understand the pathogenesis of NAFLD,
tissue proteomics is also considered to be a more effec-
tive tool. Younossi et al. constructed a model to predict
NASH and advanced hepatic fibrosis based upon protein
microarray-phosphoproteomics using liver biopsy sam-
ples, blood samples and visceral adipose tissue [49]. In
this model, using the parameters of age, race, gender, dia-
betes status, AST, phosphorylated-Akt (Ser 473) and
phosphorylated-insulin receptor substrate 1 (IRS1) (Ser
612), it was possible to predict NASH with AUC = 0.860
(81.3% sensitivity and 87.0% specificity) [49]. Charlton
et al. compared the protein expression profiles in four
groups of liver tissue samples (obese normal, simple stea-
tosis, NASH-mild [inflammation grade 1, fibrosis stage
0-1] and NASH-progressive group [fibrosis stage 2-4])
from obese patients using the combination of iTRAQ
with LC-MS/MS [50]. They identified a total of 1362
hepatic-expressed proteins, and found that a 40-kDa ker-
atin sulfate proteoglycan was significantly overexpressed
in a progressive manner in NASH (-mild and -progres-
sive), whereas, fatty acid binding protein-1 (FABP-1) was
underexpressed in both states of NASH [50].
Several groups have performed proteomic analyses using
liver tissue from patients with HCV-related chronic liver
disease. Diamond et al. performed a quantitative proteomic
analysis of HCV-infected human liver tissue from patients
at different stages of fibrosis using
16O/
18O stable isotope
labeling combined with the accurate mass and time tag
approach, and revealed that 210 of 1641 proteins, including
those associated with carbohydrate and fatty acid metabo-
lism and the mitochondrial oxidative stress response,
exhibited statistically significant differences that were asso-
ciated with the fibrosis stage [51]. Mölleken et al. compared
the protein expression in hepatocytes and cells from the
cirrhotic septa of patients with end-stage liver disease asso-
ciated with HCV infection at the time of liver transplanta-
tion using 2-DE-LC-MS/MS [52]. Several structural
proteins were upregulated in cells from fibrotic septa,
which were assumed to have arisen from activated hepatic
stellate cells. One of these identified proteins, microfibril-
associated protein-4 (MFAP-4) was subsequently measured
in serum, and were shown to increase as the fibrosis stage
increased. Although this marker was not able to discrimi-
nate between mild and moderate fibrosis, MFAP-4 was
more useful to diagnose cirrhosis associated with HCV
infection compared with alcoholic liver cirrhosis. In addi-
tion, this report could extend the concept of tissue proteo-
mics into the discovery of serum biomarkers.
D - Proteomic analysis of hepatitis B or C virus
infection
HBV and HCV can induce both acute and chronic
necroinflammatory liver disease, and chronic infection
with both viruses has a very high risk of developing into
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viral infection and/or chronic hepatitis are also neces-
sary to elucidate new potential therapeutic approaches.
However, reports of biomarkers that can predict viral
infection or the mechanism of hepatitis have not been
fully investigated.
He et al. compared sera from normal, HBV infected
low- and high-necroinflammatory scoring patients using
2-DE, and identified that the expression of seven pro-
teins, haptoglobin b and a2 chain, apolipoprotein A-I
and A-IV, a1-antitrypsin, transthyretin and DNA topoi-
somerase IIb correlated with the HBV necroinflamma-
tory scores [53]. More recently, Ren et al. performed a
serum proteomic analysis of HBV infection. They com-
pared the changes in serum proteins in patients with
acute-on-chronic liver failure (AoCLF) with those in nor-
mal subjects or in patients with chronic hepatitis B using
2-DE, and identified 12 of 23 differentially expressed pro-
teins [54]. In this analysis, serum levels of a1-acid glyco-
protein was one of the proteins that were significantly
decreased in patients with AoCLF [54]. Chen’s group per-
formed several in vitro proteomic investigations of HBV-
infected HepG2 hepatoma cells to evaluate the protein
changes associated with virus infection. Using the com-
bined methods of iTRAQ with 2D-LC-MS/MS, they
compared the protein expression in non-infected HepG2
with HBV-infected HepG2 cells to identify several pro-
teins that were down-regulated in HBV-infected cells,
including S100A6 and annexin A2 [55,56]. On the other
hand, the influence of HCV infection is often assessed
in vitro using the HCV replicon system [57]. Jacobs et al.
performed a large-scale proteome analysis of the Huh-7.5
cell line, containing a full-length HCV replicon with the
multidimensional LC-MS/MS technique [58]. Then, they
identified 4,200 proteins, including lipid metabolism-
related proteins, expressed in Huh-7.5 cells. A total of
1,500 proteins were also detected from liver biopsies
from HCV-infected patients. More recently, Singaravelu
et al. utilized a unique labeling probe, a non-directed
phenyl sulfonate ester probe, PS4, which was labeled to a
nucleophilic residue within the active site of the enzyme
molecules to profile the alteration of activity levels during
HCV replication during Huh-7 HCV subgenomic repli-
con [59]. Nineteen active proteins including protein dis-
ulfide isomerase-associated 4, heat shock 70 kDa protein
5 were then identified by 2-DE-LC-MS/MS. Thus, pro-
teomic analysis using HCV replicon is thought to be use-
ful for understanding the mechanism of HCV infection
and replication.
E - Prospects for proteomics in liver diseases
Analysis of phosphorylated or glycosylated peptides and
proteins is increasingly important in biomarker studies
[60]. In addition to identification and localization of
modified sites, analysis of their variation may provide
important clues to complex biological functions and for
exploration of disease biomarkers and new drug
development. The outline of proteomic analysis for
phosphor- and glyco-ptrotein was shown in Figure 1.
Plectin-1 (phospho-Ser-4253) and alpha-HS-glycoprotein
(phospho-Ser 138 and 312) have been identified as bio-
markers of HCC in an analysis targeting phosphorylated
proteins [61].
Differences in carbohydrate chains bound to the same
protein in cancer and normal cells are well known, and
proteomics focusing on differences in glycosylation of
proteins has been performed [62-65]. Different glycosyla-
tion patterns of proteins in HCC tissue and plasma have
been reported in a study in which HCC samples were
pretreated with lectin-bound agarose and the resulting
glycoprotein was analyzed by 2D-DIGE and MALDI-
TOF/MS. Analysis of plas m ab yn a n o - L C / M S - M S
showed increased expression of human liver carboxyles-
terase 1 (hCE1) in HCC patients [66]. Block et al. showed
that the hyperfucosylated Golgi Protein 73 (GP73) was
elevated in the serum of patients with HCC based upon
targeted glycoproteomics using the combined method of
HPLC with 2-DE [67]. Lee et al. labeled proteins in the
plasma of HCC patients and healthy controls using
iTRAQ and identified 14 high-level N-linked sugar
chains in the HCC group. Two of the associated proteins
were identified as vitronectin (Asn-169, 242) and antith-
rombin III (Asn-225), and the changes in the sugar
chains were proposed as potential markers of HCC [68].
Samples
P
Immunoprecipitation
Lectin column
G
G
G
Ti P
P Fe3+
Lectin-column
Metal-chromatography
Glycoprotein Phosphoprotein
MALDI-TOF-MS-MS  or  LC/MS-MS
Figure 1 The outline for identification of glycol- and phosphor-
protein.
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protein (AGP) was found to be higher in patients with
HBV-related HCC compared to controls, although there
was no significant difference in the total AGP level in
serum between the patients and controls [64]. Peptido-
mics targeting low-molecular-weight peptides [69] and
fragmentomics targeting protein fragments [70,71] may
also be useful in the search for liver disease markers.
Paradis et al. used the ProteinChip SELDI system to
analyze sera from 96 patients with chronic hepatitis C
who were treated with interferon and ribavirin and
found that changes in the number of protein peaks dur-
ing the treatment course was significantly greater in
patients who responded to the treatment compared to
non-responders [72]. The therapeutic effect could be
predicted with an AUROC of 0.75 using a differentiation
method based on a combination of the peak levels of 2
proteins, fibrosis stage, and viral genotype. Therefore,
proteomic analysis may also allow prediction of thera-
peutic effects and identification of proteins related to
these effects, in addition to diagnosis of liver diseases.
Conclusion
In recent decades, proteomic technologies based on
mass spectrometry have been developed, and the relia-
bility of these technologies continues to improve. Such
advancements in proteomic techniques could contribute
to the discovery of clinically useful biomarkers and the
elucidation of the molecular mechanisms involved in
disease pathogenesis. However, such advanced techni-
ques are not necessarily utilized broadly and effectively
because of the costs associated with the introduction of
these technologies and the conscious differences that
exist between developers and users of the application of
identified biomarkers in clinical practice. Thus, as devel-
opers it is essential to make it clear as to how to use
identified biomarker candidates appropriately.
In this review, we provided a survey of recent advances
of proteomic investigations and several findings focused
in liver diseases, including NAFLD, viral hepatitis, hepatic
fibrosis, liver cirrhosis, and HCC. A low correlation
between mRNA and protein expression levels has been
found using exhaustive proteine x p r e s s i o na n a l y s i s[ 7 3 ] .
Compared to detection of gene expression using DNA
microarray analysis, techniques such as time-of-flight MS
used in proteomics have relatively weak reproducibility
and operability, and have not been developed sufficiently
to allow wide use at all facilities. However, analysis of
changes in protein expression is essential to investigate
pathological conditions and reactions in vivo because
processes at the organ, tissue and cellular levels are
mostly regulated by proteins. About 20 proteins, includ-
ing albumin and immunoglobulin, account for 99% of
total serum protein, and proteins that may serve as
biomarkers are present in trace amounts that account for
the remaining 1%. Therefore, a more sensitive detection
system to search for biomarkers is required, and this
may allow discovery of clinically useful markers for all
liver diseases. In addition, clarifying the profile of glycol-
and phosphor-proteins maya l s ob ev e r yi m p o r t a n ti n
understanding the pathogenesis of HCC and other liver
diseases. The detection of such post-translational modifi-
cation of proteins may reflect the pathogenesis of disease
states more sensitively and specifically than methods that
only examine the fluctuation of protein expression, as the
profile of glycol- and phosphor-proteins in cancer cell-
surface and -secreted protein are distinct from those in
normal cells.
Proteins are assumed to be key molecules that define
the characteristics and dynamics of cells and control
biological reactions. Therefore, investigation of changes
in protein expression levelsi sv e r yi m p o r t a n ti nu n d e r -
standing disease pathology. Further advances in
proteomics techniques and establishment of simple
and quantitative performance comparable to that of
DNA microarrays are likely to promote proteomic stu-
dies and lead to further breakthroughs in clinical
proteomics.
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